Literature DB >> 34088992

Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA).

Nicolás Renna1, Daniel Piskorz2, Diego Stisman3, Diego Martinez4, Ludmila Lescano5, Sergio Vissani6, Walter Espeche7, Diego Marquez8, Roberto Parodi9, Diego Naninni10, Marcos Baroni11, Daniel Llanos12, Rocio Martinez13, Jessica Barochinner13, Gustavo Staffieri14, Fernando Lanas15, Mónica Velásquez16, Marcos Marin17, Bryan Williams18, Irene Ennis19.   

Abstract

The present document provides scientific evidence reviewed and analysed by a group of specialist clinicians in hypertension that aims to give an insight into a pharmacological strategy to improve blood pressure control. Evidence shows that most hypertensive patients will need at least two drugs to achieve blood pressure goals. There is ample evidence showing that treatment adherence is inversely related to the number of drugs taken. Observational studies show that use of drug combinations to initiate treatment reduces the time to reach the treatment goal and reduces CVD, especially with single pill combinations (SPCs). This work, based on recommendations of the Argentine Federation of Cardiology and Argentine Society of Hypertension as a reference, aims to review the more recent evidence on SPC, and to serve as guidelines for health professionals in their clinical practice and to the wider use of SPCs for the treatment of hypertension. Evidence from clinical trials on the effectiveness and adverse effects of using SPCs are provided. An analysis is also made of the main contributions of SPCs in special populations, e.g., elderly and diabetic patients, and its use in high risk and resistant hypertension. The effects of SPCs on hypertensive-mediated organ damage is also examined. Finally, we provide some aspects to consider when choosing treatments in the economic context of Latin-America for promoting the most efficient use of resources in a scarce environment and to provide quality information to decision makers to formulate safe, cost-effective, and patient-centered health policies. Finally, future perspectives and limitations in clinical practice are also discussed.

Entities:  

Year:  2021        PMID: 34088992     DOI: 10.1038/s41371-021-00557-w

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  53 in total

1.  Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group.

Authors:  L A Hebert; J W Kusek; T Greene; L Y Agodoa; C A Jones; A S Levey; J A Breyer; P Faubert; H A Rolin; S R Wang
Journal:  Hypertension       Date:  1997-09       Impact factor: 10.190

Review 2.  Polypill, hypertension and medication adherence: The solution strategy?

Authors:  D Cimmaruta; N Lombardi; C Borghi; G Rosano; F Rossi; A Mugelli
Journal:  Int J Cardiol       Date:  2017-11-23       Impact factor: 4.164

3.  Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.

Authors:  Morris J Brown; Gordon T McInnes; Cheraz Cherif Papst; Jack Zhang; Thomas M MacDonald
Journal:  Lancet       Date:  2011-01-12       Impact factor: 79.321

4.  The Hypertension Optimal Treatment study and the importance of lowering blood pressure.

Authors:  L Hansson
Journal:  J Hypertens Suppl       Date:  1999-02

5.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Authors:  Kenneth Jamerson; Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Victor Shi; Allen Hester; Jitendra Gupte; Marjorie Gatlin; Eric J Velazquez
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

6.  Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.

Authors:  David S Wald; Malcolm Law; Joan K Morris; Jonathan P Bestwick; Nicholas J Wald
Journal:  Am J Med       Date:  2009-03       Impact factor: 4.965

7.  Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients).

Authors:  Kálmán Tóth
Journal:  Am J Cardiovasc Drugs       Date:  2014-04       Impact factor: 3.571

8.  24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.

Authors:  Y Lacourcière; N Crikelair; R D Glazer; J Yen; D A Calhoun
Journal:  J Hum Hypertens       Date:  2011-01-20       Impact factor: 3.012

9.  Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence.

Authors:  Pankaj Gupta; Prashanth Patel; Branislav Štrauch; Florence Y Lai; Artur Akbarov; Gaurav S Gulsin; Alison Beech; Věra Marešová; Peter S Topham; Adrian Stanley; Herbert Thurston; Paul R Smith; Robert Horne; Jiří Widimský; Bernard Keavney; Anthony Heagerty; Nilesh J Samani; Bryan Williams; Maciej Tomaszewski
Journal:  Hypertension       Date:  2017-08-28       Impact factor: 10.190

10.  Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.

Authors:  Thomas M MacDonald; Bryan Williams; Mark Caulfield; J Kennedy Cruickshank; Gordon McInnes; Peter Sever; David J Webb; Isla S Mackenzie; Jackie Salsbury; Steve Morant; Ian Ford; Morris J Brown
Journal:  BMJ Open       Date:  2015-08-07       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.